By Charlotte Babbin
In October 2019, the FDA approval of the new HIV-prevention drug Descovy was met with great excitement by doctors, HIV researchers, and many people at risk of HIV infection. Descovy functions as a pre-exposure prophylaxis (PrEP), medicine taken to prevent HIV infection. The second ever drug approved for PrEP, in research trials, Descovy reduced kidney and bone health side effects.
Not everyone, however, applauded the approval of this drug. To many people’s disappointment, Descovy was not approved for use ... More
The post In the Fight Against HIV, Gendered Assumptions Have Deadly Consequences appeared first on Our Bodies Ourselves.